Novo Nordisk A/S (NYSE:NVO) announced a Semi-Annual dividend on Friday, August 9th, NASDAQ reports. Stockholders of record on Monday, August 19th will be paid a dividend of 0.318 per share on Tuesday, August 27th. The ex-dividend date of this dividend is Friday, August 16th.

Novo Nordisk A/S has raised its dividend payment by an average of 19.3% annually over the last three years. Novo Nordisk A/S has a dividend payout ratio of 44.0% indicating that its dividend is sufficiently covered by earnings. Equities analysts expect Novo Nordisk A/S to earn $2.81 per share next year, which means the company should continue to be able to cover its $1.11 annual dividend with an expected future payout ratio of 39.5%.

Shares of NVO opened at $51.11 on Wednesday. The stock has a market capitalization of $123.15 billion, a P/E ratio of 20.28, a P/E/G ratio of 2.30 and a beta of 0.60. Novo Nordisk A/S has a one year low of $41.23 and a one year high of $52.83. The company has a debt-to-equity ratio of 0.07, a current ratio of 0.96 and a quick ratio of 0.66. The company has a 50-day simple moving average of $49.53.

Several equities research analysts have issued reports on the company. Zacks Investment Research upgraded Novo Nordisk A/S from a “sell” rating to a “hold” rating and set a $50.00 price objective on the stock in a report on Monday, July 15th. Deutsche Bank downgraded shares of Novo Nordisk A/S from a “buy” rating to a “hold” rating and set a $52.42 price target for the company. in a research report on Thursday, June 20th. Pareto Securities raised shares of Novo Nordisk A/S from a “hold” rating to a “buy” rating in a research report on Monday, August 5th. Barclays raised shares of Novo Nordisk A/S from an “underweight” rating to an “equal weight” rating and set a $51.85 price target on the stock in a report on Tuesday, June 11th. Finally, Credit Suisse Group upgraded shares of Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a research note on Monday, April 29th. One equities research analyst has rated the stock with a sell rating, ten have issued a hold rating and six have issued a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $111.58.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes Care and Obesity, and Biopharmaceuticals. The Diabetes Care and Obesity segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral anti-diabetic products, obesity, and other chronic diseases.

Further Reading: How is a management fee different from a performance fee?

Dividend History for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.